Cargando…
Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma
Synovial sarcoma is an aggressive malignancy that generally affects adolescents and young adults and is characterized by high rates of recurrence and metastasis, with a 10-year survival rate of about 50%. The fusion oncoprotein SS18-SSX, the product of a pathognomonic chromosomal translocation t(X;1...
Autores principales: | Raquib, Ainiah Rushdiana, Hofvander, Jakob, Ta, Monica, Nielsen, Torsten O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444294/ https://www.ncbi.nlm.nih.gov/pubmed/35880992 http://dx.doi.org/10.1097/PAI.0000000000001049 |
Ejemplares similares
-
SS18-SSX drives CREB activation in synovial sarcoma
por: Cyra, Magdalene, et al.
Publicado: (2022) -
The clinical implication of SS18-SSX fusion gene in synovial sarcoma
por: Ren, T, et al.
Publicado: (2013) -
Usefulness of SS18-SSX antibody as a diagnostic marker for pulmonary metastatic synovial sarcoma
por: Miura, Kentaro, et al.
Publicado: (2021) -
Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma
por: Ishii, Midori, et al.
Publicado: (2018) -
Truncated SSX Protein Suppresses Synovial Sarcoma Cell Proliferation by Inhibiting the Localization of SS18-SSX Fusion Protein
por: Yoneda, Yasushi, et al.
Publicado: (2013)